BIODELIVERY SCIENCES INTERNATIONAL INC
10QSB, 2000-11-14
BLANK CHECKS
Previous: INETVISIONZ COM INC, NT 10-Q, 2000-11-14
Next: NETVOICE TECHNOLOGIES CORP, 10QSB, 2000-11-14




                               UNITED STATES
                      SECURITIES AND EXCHANGE COMMISSION
                            Washington, D.C. 20549

                                 Form 10-QSB

[x]           QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
              SECURITIES EXCHANGE ACT OF 1934
              For the period ended  - September 30, 2000

                                      OR

[ ]           TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
       	      SECURITIES EXCHANGE ACT OF 1934
              For the transition period from

                      Commission file number 0-28931

   BIODELIVERY SCIENCES INTERNATIONAL, INC. (F/K/A/ MAS ACQUISITION XXIII CORP.)
              (Name of Small Business Issuer in its charter)



                Indiana                                       35-2089858
    (State or other jurisdiction of                       (I.R.S. Employer
     incorporation or organization                      Identification Number)


     17 North Governor St., Evansville, Indiana           47711
     (Address of principal executive offices)          (Zip Code)

     Registrant's telephone number, including area code: (812) 425-1050



     Securities registered under Section 12(b) of the Act: None

     Securities registered under Section 12(g) of the Act:

               Common Stock, $.001 par value per share
                           (Title or class)

     Indicate by check mark whether the Registrant (1) has filed all reports
     required to be filed by Section 13 or 15(D) of the securities Exchange Act
     of 1934 during the preceding 12 months (or for such shorter period that the
     Registrant was required to file such reports), and  (2) has been subject to
     such filing requirements for the past 90 days.	YES [x]   NO [ ]

     As of September 30, 2000, the Registrant has outstanding 8,272,400 shares
     of Common Stock.

                                       1
<PAGE>

 			BIODELIVERY SCIENCES INTERNATIONAL, INC.

                            Form 10-QSB

                         Quarterly Report

                        September 30, 2000


PART I.  FINANCIAL INFORMATION

<TABLE>
<CAPTION>

ITEM 1.  FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

                                                                 Page
<S>                                                              <C>
(1) Financial Statements
     Balance Sheet at September 30, 2000                         3
     Statements of Operations for the three months and nine
        months ended September 30, 2000 and 1999  and the period
        from inception (January 6, 1997)
        to September 30, 2000                                    4
     Statements of Cash Flows for the nine months
        ended September 30, 2000 and 1999 and the period
        from inception (January 6, 1997)
        to September 30, 2000                                    5
     Notes to Unaudited Financial Statements                     6

(2) Management's Discussion and Analysis of Financial Condition and
      Results of Operation                                      			     7

PART II. OTHER INFORMATION

(6)  Exhibits and Reports on Form 8-K                            8

SIGNATURES                                                       9
</TABLE>

                                       2
<PAGE>

 		BIODELIVERY SCIENCES INTERNATIONAL, INC.
               (A Development Stage Company)
                      Balance Sheet


<TABLE>
<CAPTION>
Assets

<S>                                               <C>
								  Sept. 30, 2000
								  (unaudited)
Current assets:
  Total current assets                            $      -

Other assets:
  Organization costs net of amortization of $68         22
                                                  --------
     Total assets                                 $     22
                                                  ========

Liabilities and Stockholders' Equity

Current liabilities:
  Total current liabilities                       $      -

Stockholders' equity:
Preferred stock, $.001 par value
   20,000,000 shares authorized,
   none issued or outstanding                            -
Common stock, $.001 par value,
   80,000,000 shares authorized,
   8,272,400 shares issued and
   outstanding                                         111
   Deficit accumulated during the
    development stage                                  (89)
                                                  --------
     Total liabilities and stockholders' equity   $     22
                                                  ========
</TABLE>


     The accompanying notes are an integral part of these the financial
             statements.



                                   3
<PAGE>

BIODELIVERY SCIENCES INTERNATIONAL, INC.
        (A Development Stage Company)
                               Statements of Operations
                                     (Unaudited)

<TABLE>
<CAPTION>
                                Three Months         Nine Months       Inception
                               Ended  Sept. 30,     Ended Sept. 30, (January 6, 1997)
                               ---------------     ---------------        to
                               2000      1999      2000     1999     Sept. 30, 2000
                               ---------------     ---------------   --------------
<S>                            <C>       <C>       <C>       <C>         <C>
Revenue                        $  -      $  -      $  -      $  -        $   -

Costs and expenses:
 General and Administrative       4         4        14        14           89
                               ----      ----      ----      ----        -----
   Net (loss)                  $ (4)     $ (4)     $(14)     $(14)       $ (89)
                               ====      ====      ====      ====        =====

Per share information:

 Weighted average number
 of common shares
 outstanding
 basic and diluted  8,519,900 8,519,800 8,519,900 8,519,800    8,516,000
                          ========= ========= ========= =========    =========

 (Loss) per share
 basic and diluted      $(.00)    $(.00)    $(.00)    $(.00)       $(.00)
                              =====     =====     =====     =====        =====
</TABLE>


The accompanying notes are an integral part of these financial statements.



                                         4
<PAGE>

 				BIODELIVERY SCIENCES INTERNATIONAL, INC.
                          (A Development Stage Company)
                             Statements of Cash Flows
                                  (Unaudited)

<TABLE>
<CAPTION>
                                                    Nine Months            Inception
                                                   Ended Sept. 30,      (January 6, 1997)
                                               ------------------------       to
                                                  2000         1999      Sept. 30, 2000
                                               -----------  ----------- ----------------
<S>                                              <C>         <C>           <C>
Cash Flows From Operating Activities:
  Net (loss)                                     $   (14)    $   (14)      $      (89)
Adjustments to reconcile net (loss) to net cash
 provided by (used in) operating activities:
  Amortization                                        14          14               68
 -
                                                 -------     -------       ----------
Cash flows from investing activities:
Net cash provided by (used in)
  investing activities                                 -           -                -
                                                 -------     -------       ----------
Cash flows from financing activities:
Net cash provided by (used in)
  financing activities                                 -           -                -
                                                 -------     -------       ----------
Net increase (decrease) in cash and
  cash equivalents                                     -           -                -
                                                 -------     -------       ----------
Beginning cash and cash equivalents                    -           -                -
                                                 -------     -------       ----------
Ending cash and cash equivalents                 $     -     $     -       $        -
                                                 =======     =======       ==========

</TABLE>


 The accompanying notes are an integral part of these the financial statements.


                                    5
<PAGE>

 			BIODELIVERY SCIENCES INTERNATIONAL, INC.
                      (A Development Stage Company)
                      Notes to Financial Statements
                        As of September 30, 2000

(1) Basis of Presentation

The accompanying unaudited financial statements have been prepared in accordance
with instructions to Form 10-QSB and do not include all of the information and
footnotes  required by generally accepted accounting principles for complete
financial statements.  In the opinion of management, all adjustments
(consisting only of normal recurring adjustments) considered necessary
for a fair presentation have been included.  The results of operations for
the periods presented are not
necessarily indicative of the results to be expected for the full year.  The
financial
statements should be read in conjunction with the financial statemsn and noted
thereto, together with management's discussion and analysis of financial
condition and results of operations included in the Company's Form 10-SB.



(2) Earnings Per Share

The Company calculates net income (loss) per share as required by SFAS No. 128,
"Earnings per Share." Basic earnings (loss) per share is calculated by dividing
net income (loss) by the weighted average number of common shares outstanding
for the period. Diluted earnings (loss) per share is calculated by dividing net
income (loss) by the weighted average number of common shares and dilutive
common stock equivalents outstanding. During the periods presented common stock
equivalents were not considered as their effect would be anti-dilutive.

(3) Income Taxes


(3) Stockholders' Equity

On September 29, 2000 247,500 shares of the Company's $.001 par value common
stock were returned to the Company for no consideration and cancelled.

(4) Subsequent Events

Effective October 9, 2000, the Company entered into a contribution agreement
with Hopkins Capital Group (Hopkins), which was previously an unrelated third
party.  As a result of this agreement, Hopkins acquired 97.7 percent of the
voting
common stock of the Company.  Immediately following this transaction there were
15,350,000 shares of common stock outstanding.  Hopkins did not have any


Effective October 10, 2000, the Company acquired preferred stock of BioDelivery
Sciences, Inc. (BDS) representing 80% of the voting rights of BDS in exchange
for a purchase price of $15,000,000.  The purchase price was payable $1,000,000
in cash upon closing and $14,000,000 in notes payable maturing through
December 2002.  BDS is a development stage company creating the ability
to deliver certain pharmaceutical drugs and vaccines orally.




                                   6
<PAGE>

ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
        AND RESULTS OF OPERATION


The following discussion should be read in conjunction with the information
contained in the financial statements of the Company and the Notes thereto
appearing elsewhere herein.

Results of Operations - Inception (January 6, 1997) through September 30, 2000.

The Company is considered to be in the development stage as defined in
        Statement of Financial Accounting Standards No. 7. There have been no
        operations since inception.



Plan of Operation.

On October 10, 2000, the Company acquired a controlling interest in BioSciences
Delivery Systems Inc. (BDS).  As a result, the Company expects to continue the
development of BDS's principal products, including the development of oral
means to deliver certain drugs and vaccines for human and veter9inary uses.
These drugs and vaccines include Amphotericin B, Insulin and various vaccines.
There is no assurance that the Company will successfully complete the testing
of these products or obtain regulatory approval associated with these products.



Liquidity and Capital Resources.

The Company's acquisition and resulting operations of BDS will require
additional capital to complete the testing and approval process relative to the
products of BDS.  Prior to the acquisition b the Company, the principal sources
of
funding for the development of BDS's products included funded research contracts
from both commercial and public sector sources.  While the Company believes
it can secure adequate resources to continue to fund the operations and
development of BDS's products there can be no assurance that such funds will be
 available or that any resulting research and development will be successful.




The Company has no cash as of September 30, 2000.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

In connection with the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995 (the "Reform Act"), the Company is hereby
providing cautionary statements identifying important factors that could cause
the Company's actual results to differ materially from those projected in
forward-looking statements (as such term is defined in the Reform Act) made by
or on behalf of the Company herein or orally, whether in presentations, in
response to questions or otherwise.  Any statements that express, or involve
discussions as to expectations, beliefs, plans, objectives, assumptions or
future events or performance (often, but not always, through the use of words or
phrases such as "will result", "are expected to", "will continue", "is
anticipated", "estimated", "projection" and "outlook") are not historical facts
and may be forward-looking and, accordingly, such statements involve estimates,
assumptions, and uncertainties which could cause actual results to differ
materially from those expressed in the forward-looking statements.  Such
uncertainties include, among others, the following:  (i) the Company's ability
to obtain additional financing to implement its business strategy;  (ii) the
financial condition of the Company's clients;  (iii) imposition of new
regulatory requirements affecting the Company;  (iv) a downturn in general
economic conditions (v) the delay or failure to properly manage growth and
successfully integrate acquired companies and operations;  (vi) lack of
geographic diversification;  and (vii) other factors which are described in
further detail in the Company's filings with the Securities and Exchange
Commission.

The Company cautions that actual results or outcomes could differ materially
from those expressed in any forward-looking statements made by or on behalf of
the Company.  Any forward-looking statement speaks only as of the date on which
such statement is made, and the Company undertakes no obligation to update any
forward-looking statement or statements to reflect events or circumstances after
the date on which such statement is made or to reflect the occurrence of
unanticipated events.  New factors emerge from time to time, and it is not
possible for management to predict all of such factors.  Further, management
cannot assess the impact of each such factor on the business or the extent to
which any factor, or combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements.

                                             7
<PAGE>

Part II.  OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS
        None

ITEM 2. CHANGES IN SECURITIES
        None

ITEM 3. DEFAULTS UPON SENIOR SECURITIES
        None

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
        None

ITEM 5. OTHER INFORMATION

  On September 29, 2000, five of our shareholders returned a total of 247,500
shares of our Common Stock for cancellation.  We paid no consideration and our
parent company, MAS Capital Inc. agreed to issued 2,500 shares of Common Stock
of MAS Capital Inc. as consideration.

 Effective October 9, 2000, we entered into a Contribution Agreement with
Subscribers (the "Hopkins Capital Group"), listed in Exhibit 1.0 of the
Contribution
Agreement, incorporated by reference, whereby we agreed to exchange 15,000,000
shares of our common stock for the properties listed in Exhibit 1.1 of the
Contribution Agreement.  The shares of our common stocks will be issued to the
individuals in the amounts specified in Exhibit 1.0 of the Contribution
Agreement.
After the exchange, we will have a total of 15,350,000 shares of common
stock outstanding.

Effective October 9, 2000, the Company entered into a contribution agreement
with Hopkins Capital Group (Hopkins), which was previously any unrelated
third party.  As a result of this agreement, Hopkins acquired 97.7 percent of
the
voting common stock of the Company.  Immediately following this transaction
there were 15,350,000 shares of common stock outstanding.  Hopkins did not
have any operations prior to this transaction.



Effective October 10, 2000, the Company acquired preferred stock of BioDelivery
Sciences, Inc. (BDS) representing 80% of the voting rights of BDS in exchange
for a purchase price of $15,000,000.  The purchase price was payable $1,000,000
in cash upon closing and $14,000,000 in notes payable maturing through December
2002 BDS is a development stage company creating the ability to deliver certain
pharmaceutical drugs and vaccines orally.





ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

A. Exhibits
   27.1 Financial Data Schedule (For SEC purposes only)

B. Reports on Form 8-K
   None

                                       8
<PAGE>

SIGNATURES

	 Pursuant to the requirements of Section 13 or 15(d) of the Securities
and Exchange Act of 1934, the Registrant has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.



BIODELIVERY SCIENCES INTERNATIONAL, INC.


Date: October 12, 2000

                                     By: /s/ Dr. Frank O'Donnell
                                     ----------------------------------
                                     Dr. Frank O'Donnell
			             Chairman, President and Director


                                       9
<PAGE>

This schedule contains summary financial information extracted from the
Balance Sheet at September 30, 2000 (unaudited) and the Statement of
Operations for the nine months ended September 30, 2000 (unaudited) and
is qualified in its entirety by reference to such financial statements.

<TABLE>
<S>                                    <C>
PERIOD-TYPE                          9-MOS
FISCAL-YEAR-END                      DEC-31-2000
PERIOD-END                           SEP-30-2000
CASH                                 0
SECURITIES                           0
RECEIVABLES                          0
ALLOWANCES                           0
INVENTORY                            0
CURRENT-ASSETS                       0
PP&E                                 0
DEPRECIATION                         0
TOTAL-ASSETS                        22
CURRENT-LIABILITIES                  0
BONDS                                0
PREFERRED-MANDATORY                  0
PREFERRED                            0
COMMON                             111
OTHER-SE                           (89)
TOTAL-LIABILITY-AND-EQUITY          22
SALES                                0
TOTAL-REVENUES                       0
CGS                                  0
TOTAL-COSTS                          0
OTHER-EXPENSES                     (14)
LOSS-PROVISION                       0
INTEREST-EXPENSE                     0
INCOME-PRETAX                      (14)
INCOME-TAX                           0
INCOME-CONTINUING                    0
DISCONTINUED                         0
EXTRAORDINARY                        0
CHANGES                              0
NET-INCOME                         (14)
EPS-PRIMARY                          0
EPS-DILUTED                          0

</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission